Go to AAD Home
Donate For Public and Patients Store Search

Go to AAD Home
Welcome!
Advertisement
Advertisement

Emerging diseases resource center


Banner image for AAD Emerging diseases

Welcome to the American Academy of Dermatology’s hub for emerging diseases. The Academy’s Emerging Diseases Task Force has curated and developed these scientific resources to assist members in the recognition, management, and reporting of emerging threats. Please check back regularly for disease alerts and new resources.

Card illustration for Emerging Diseases registry
Emerging diseases registry

Access our registry for emerging diseases, including mpox, dermatophytosis, and COVID-19.

Alpha-gal syndrome card image
Alpha-gal syndrome resources

Access information and resources on Alpha-gal syndrome.

Viral trends

Access information and resources on viral trends.

Dermatophilosis resources image card
Dermatophilosis resources

Access information and resources on Dermatophilosis.

Blue banner showing microbes with text reading Return of Vaccine-preventable Diseases.
Return of vaccine-preventable diseases

Access information on various vaccine-preventable diseases.

Hemorrhagic Fevers card
Hemorrhagic fevers

Access information on viral hemorrhagic fevers, such as hantavirus.

Card image for AAD measles resources
Measles resources

Learn about the current measles outbreak, recognizing measles, vaccine information, and more.

Card illustration for antifungal-resistant dermatophytes
Emerging dermatophytes

Access our information on antimicrobial-resistant and other emerging dermatophytes.

Card illustration for monkeypox
Mpox resources

Access clinical guidance from the Academy and the CDC on recognizing and treating mpox.

Illustration for AM2020 FAQs
COVID-19 clinical resources

Access our information on biologics or the COVID-19 dermatology registry.


CDC request for cases of severe chromoblastomycosis

Dear Dermatologist,

I am reaching out from the Laboratory of Clinical Immunology and Microbiology at the NIH/NIAID regarding chromoblastomycosis. Our group has been developing translational research efforts focused on the immunopathogenesis of severe and refractory chromoblastomycosis, and emerging data from these studies suggest that targeted adjunct immunomodulatory approaches may have the potential to help induce clinical remission in selected individuals with difficult-to-treat disease.

To date, much of our clinical experience and collaborations have involved cases outside the United States. We would be very interested in connecting with dermatologists in the US who may currently care for individuals with severe, refractory, extensive, or relapsing chromoblastomycosis, particularly cases with suboptimal responses to conventional antifungal and/or surgical approaches.

Our goal would be to establish collaborative discussions regarding such cases, with the possibility of patient evaluation through NIH clinical research protocols, and consideration of investigational therapeutic approaches where appropriate.

If you are aware of such patients or interested in discussing further, please feel free to contact me directly at lionakism@niaid.nih.gov.

Best regards,

Michail S. Lionakis, MD, ScD
Chief, Laboratory of Clinical Immunology and Microbiology
Chief, Fungal Pathogenesis Section
NIAID/NIH


Alert us to emerging diseases

Use our form to alert the Academy’s task force to an emerging disease.

Submit emerging disease

STI / STD resources

Download a PDF of our resources on sexually transmitted infections / diseases.

Access PDF

Alerts and brief updates

Below is a list of links and limited information about various emerging diseases.


Advertisement
Advertisement
Advertisement